Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Ramachandran Venkitaraman"'
Autor:
Begoña de las Heras, Kamal S. Saini, Frances Boyle, Felipe Ades, Evandro de Azambuja, Ivana Bozovic-Spasojevic, Marco Romano, Marta Capelan, Rajeev Prasad, Pugazhenthi Pattu, Christophe Massard, Chia Portera, Monika Lamba Saini, Brajendra Prasad Singh, Ramachandran Venkitaraman, Richard McNally, Manuela Leone, Enrique Grande, Sudeep Gupta
Publikováno v:
Oncology and Therapy, Vol 8, Iss 2, Pp 171-182 (2020)
Abstract The coronavirus disease-2019 (COVID-19) pandemic has had a significant impact on patients with underlying malignancy. In this article, we summarize emerging data related to patients with cancer and COVID-19. Among patients with COVID-19, a h
Externí odkaz:
https://doaj.org/article/f26b014f9fa94fed8d0805a4d4bad547
Autor:
Ravindra Mukkunda, Ramachandran Venkitaraman, Khin Thway, Toon Min, Cyril Fisher, Alan Horwich, Ian Judson
Publikováno v:
Sarcoma, Vol 2009 (2009)
Background. Ewing's sarcoma of extraskeletal origin is uncommon and that is of primary renal origin in adults are rare. There is no consensus on the optimal management of Ewing's tumors of renal origin. Methods. A retrospective review of the clinical
Externí odkaz:
https://doaj.org/article/92a334d8d91b4ad3ba764888c463f87e
Autor:
Sacha J Howell, Angela Casbard, Margherita Carucci, Kate Ingarfield, Rachel Butler, Sian Morgan, Magdalena Meissner, Catherine Bale, Pavel Bezecny, Sarah Moon, Chris Twelves, Ramachandran Venkitaraman, Simon Waters, Elza C de Bruin, Gaia Schiavon, Andrew Foxley, Robert H Jones
Publikováno v:
Howell, S J, Casbard, A, Carucci, M, Ingarfield, K, Butler, R, Morgan, S, Meissner, M, Bale, C, Bezecny, P, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, de Bruin, E C, Schiavon, G, Foxley, A & Jones, R H 2022, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION) : overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial ', The Lancet. Oncology, vol. 23, no. 7, pp. 851-864 . https://doi.org/10.1016/S1470-2045(22)00284-4
BACKGROUND: Capivasertib, an AKT inhibitor, added to fulvestrant, was previously reported to improve progression-free survival in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer. The ben
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b8b7c1cc7c7d91a6ed98ec5f578778f
https://doi.org/10.1016/s1470-2045(22)00284-4
https://doi.org/10.1016/s1470-2045(22)00284-4
Autor:
Gaurav Kapur, Helen McNair, Isabelle Syndikus, Vibeke N. Hansen, Rebecca Lewis, Robert Huddart, John Staffurth, Hybrid Investigators, A. Baker, Simon Hughes, S. Moinuddin, Alison Birtle, Gail Horan, Anita Mitra, Emma Hall, Emma Patel, Ann Henry, Stephanie Gibbs, Shaista Hafeez, Yvonne Rimmer, Vincent Khoo, Ramachandran Venkitaraman, Catalina Vassallo-Bonner, Monisha Dewan
Publikováno v:
International Journal of Radiation Oncology, Biology, Physics
Huddart, R, Hafeez, S, Lewis, R, McNair, H, Syndikus, I, Henry, A, Staffurth, J, Dewan, M, Vassallo-Bonner, C, Moinuddin, S A, Birtle, A, Horan, G, Rimmer, Y, Venkitaraman, R, Khoo, V, Mitra, A, Hughes, S, Gibbs, S, Kapur, G, Baker, A, Hansen, V N, Patel, E, Hall, E & HYBRID Investigators 2021, ' Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer ', International Journal of Radiation Oncology, Biology, Physics, vol. 110, no. 2, pp. 412-424 . https://doi.org/10.1016/j.ijrobp.2020.11.068
Huddart, R, Hafeez, S, Lewis, R, McNair, H, Syndikus, I, Henry, A, Staffurth, J, Dewan, M, Vassallo-Bonner, C, Moinuddin, S A, Birtle, A, Horan, G, Rimmer, Y, Venkitaraman, R, Khoo, V, Mitra, A, Hughes, S, Gibbs, S, Kapur, G, Baker, A, Hansen, V N, Patel, E, Hall, E & HYBRID Investigators 2021, ' Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer ', International Journal of Radiation Oncology, Biology, Physics, vol. 110, no. 2, pp. 412-424 . https://doi.org/10.1016/j.ijrobp.2020.11.068
PURPOSE: Hypofractionated radiation therapy can be used to treat patients with muscle-invasive bladder cancer unable to have radical therapy. Toxicity is a key concern, but adaptive plan-of the day (POD) image-guided radiation therapy delivery could
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bedce7796f411b472a27a67e5ba5926a
https://doi.org/10.1016/j.ijrobp.2020.11.068
https://doi.org/10.1016/j.ijrobp.2020.11.068
Autor:
Johnathan K, Joffe, Fay H, Cafferty, Laura, Murphy, Gordon J S, Rustin, Syed A, Sohaib, Rhian, Gabe, Sally P, Stenning, Elizabeth, James, Dipa, Noor, Simona, Wade, Francesca, Schiavone, Sarah, Swift, Elaine, Dunwoodie, Marcia, Hall, Anand, Sharma, Jeremy, Braybrooke, Jonathan, Shamash, John, Logue, Henry H, Taylor, Ivo, Hennig, Jeff, White, Sarah, Rudman, Jane, Worlding, David, Bloomfield, Guy, Faust, Hilary, Glen, Rachel, Jones, Michael, Seckl, Graham, MacDonald, Thiagarajan, Sreenivasan, Satish, Kumar, Andrew, Protheroe, Ramachandran, Venkitaraman, Danish, Mazhar, Victoria, Coyle, Martin, Highley, Tom, Geldart, Robert, Laing, Richard S, Kaplan, Robert A, Huddart
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(22)
PURPOSE Survival in stage I seminoma is almost 100%. Computed tomography (CT) surveillance is an international standard of care, avoiding adjuvant therapy. In this young population, minimizing irradiation is vital. The Trial of Imaging and Surveillan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32509283fdd8f055e025757fc245aebc
https://pubmed.ncbi.nlm.nih.gov/35298280
https://pubmed.ncbi.nlm.nih.gov/35298280
Autor:
Brajendra Prasad Singh, Rajeev Prasad, Marco Romano, Marta Capelán, Evandro de Azambuja, Chia Portera, Kamal S Saini, Monika Lamba Saini, Frances M. Boyle, Felipe Ades, Enrique Grande, Ivana Bozovic-Spasojevic, Ramachandran Venkitaraman, Richard J. Q. McNally, Christophe Massard, Begoña de las Heras, Sudeep Gupta, Manuela Leone, Pugazhenthi Pattu
Publikováno v:
Oncology and Therapy
Scientia
Oncology and Therapy, Vol 8, Iss 2, Pp 171-182 (2020)
Scientia
Oncology and Therapy, Vol 8, Iss 2, Pp 171-182 (2020)
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Càncer; Immuno-oncologia Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cáncer; Inmuno-oncología Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cancer; Immuno-oncology The coronavirus disease-2019 (COVID-19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e741a0f58f49cdfb5872449d4420a7d
https://doi.org/10.1007/s40487-020-00124-2
https://doi.org/10.1007/s40487-020-00124-2
Autor:
Robert Hugh Jones, Angela Claire Casbard, Margherita Carucci, Kate Ingarfield-Herbert, Rachel Butler, Sian Morgan, Magdalena Meissner, Catherine Jane Bale, Pavel Bezecny, Sarah Moon, Chris Twelves, Ramachandran Venkitaraman, Simon Waters, Elza De Bruin, Gaia Schiavon, Andrew Foxley, Sacha Jon Howell
Publikováno v:
Journal of Clinical Oncology. 40:1005-1005
1005 Background: Previous results from the Phase 2 FAKTION trial (NCT01992952) showed progression free survival (PFS) in patients with aromatase inhibitor (AI) resistant ER+/HER2− advanced breast cancer was significantly longer with fulvestrant plu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5fba49c3725184d69b38b0126b99475
https://doi.org/10.1200/jco.2022.40.16_suppl.1005
https://doi.org/10.1200/jco.2022.40.16_suppl.1005
Autor:
Ramachandran Venkitaraman, Manuela Leone, Giuseppe Curigliano, Martine Poelman, Philippe Aftimos, Gopalakrishnan Srinivasan, Javier de Castro, Begoña de las Heras, Sanjeev Verma, Monika Lamba Saini, Kamal S Saini
Publikováno v:
The Lancet. Haematology
The Lancet Haematology
The Lancet Haematology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba05193f895012e5ffe4dcec4fa38e3c
http://europepmc.org/articles/PMC7195053
http://europepmc.org/articles/PMC7195053
Autor:
Catherine Jane Bale, Rachel Butler, S Waters, Angela C. Casbard, Sarah Moon, Andrew Foxley, Ramachandran Venkitaraman, Catrin Cox, Johnathan Joffe, Tracie-Ann Madden, Fouad S Alchami, Margherita Carucci, Robert H. Jones, Chris Twelves, Pavel Bezecny, Sacha J Howell
Publikováno v:
Jones, R, Casbard, A, Carucci, M, Cox, C, Butler, R, Alchami, F, Madden, T-A, Bale, C, Bezecny, P, Joffe, J, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, Foxley, A & Howell, S 2020, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION) : a multicentre, randomised, controlled, phase 2 trial ', The Lancet Oncology, vol. 21, no. 3, pp. 345-357 . https://doi.org/10.1016/S1470-2045(19)30817-4
Background Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of, the serine/threonine kinase, Akt. Akt inhibitors are anticipated to have maximal efficacy in combination with chemotherapy, targeted, or anti-hormonal dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be3e1775f72f2c39bba92c189237cd97
https://pubmed.ncbi.nlm.nih.gov/32359499
https://pubmed.ncbi.nlm.nih.gov/32359499
Publikováno v:
Journal of Clinical Oncology. 38:e17610-e17610
e17610 Background: External Beam radiotherapy is a standard treatment for patients with intermediate risk localised prostate cancer. Commonly the radiotherapy plan is delivered in two phases with adequate margins, the first phase to the prostate and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfdfe68eb527cb10b9e110e41e3ee94c
https://doi.org/10.1200/jco.2020.38.15_suppl.e17610
https://doi.org/10.1200/jco.2020.38.15_suppl.e17610